Journal cover image: Fluorescently labeled pHLIP® peptides targeting breast cancer tumor in mouse. Pilon-Thomas et al., J Cancer Res, 2016
Our overall goal is to improve patient outcomes by facilitating widespread clinical adoption of pH technology to advance diagnostics and treatment of various diseases including different types of cancers.
Our business strategy is to develop particular applications either independently or through partnership/collaboration.
Cybrexa Therapeutics holds exclusive rights for the development of particular pHLIP® based therapeutic products.
pHLIP® based research reagents could be obtained from the authorized manufacturers and distributors.
Integral to our business strategy is the proliferation of our technology via sublicensing deals with established companies and uniquely-positioned startups. Please contact us